María Dolores González-Ripoll Navarro

TL;DR: Avoidance of fluoroquinolone use in high-risk patients should be considered whenever possible in order to avoid the selection of these organisms.

TL;DR: Empirical treatment of sepsis potentially caused by E. coli may need to be reconsidered in areas where such ESBL-producing isolates are present, and empirical therapy with cephalosporins or fluoroquinolones was associated with a higher mortality rate.

TL;DR: The results suggest that both acquisition from a common source and person-to-person transmission might contribute to ESBL dissemination.

TL;DR: In Europe, improvement of national antimicrobial resistance surveillance systems and better alignment between human and veterinary surveillance systems in Europe must become a scientific and political priority, coordinated with international stakeholders within a global approach to reduce the burden of antimicrobial resistant bacteria.

TL;DR: The epidemiology of ESBL-producing E. coli as a cause of nosocomial infection is complex and previous oxyimino-beta-lactam use, diabetes, and ultimately fatal or nonfatal underlying diseases were independent risk factors for infection or colonization with CTX-M-producing isolates, whereas previous fluoroquinolone use was associated with infection or Colonization with SHV-TEM-producing isolate.